Myriad Genetics, Inc.

Symbol: MYGN

NASDAQ

21.6

USD

Market price today

  • -7.5210

    P/E Ratio

  • -0.4011

    PEG Ratio

  • 1.94B

    MRK Cap

  • 0.00%

    DIV Yield

Myriad Genetics, Inc. (MYGN) Stock Price & Analysis

Shares Outstanding

89.87M

Gross Profit Margin

0.69%

Operating Profit Margin

-0.37%

Net Profit Margin

-0.37%

Return on Assets

-0.24%

Return on Equity

-0.35%

Return on Capital Employed

-0.29%

Company general description and statistics

Sector: Healthcare
Industry: Diagnostics & Research
CEO:Mr. Paul J. Diaz
Full-time employees:2700
City:Salt Lake City
Address:320 Wakara Way
IPO:1995-10-06
CIK:0000899923

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

General Outlook

In simple terms, Myriad Genetics, Inc. has 89.875 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.689% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.370%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.374%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.239% return, is a testament to Myriad Genetics, Inc.'s adeptness in optimizing resource deployment. Myriad Genetics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.350%. Furthermore, the proficiency of Myriad Genetics, Inc. in capital utilization is underscored by a remarkable -0.289% return on capital employed.

Stock Prices

Myriad Genetics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $20.03, while its low point bottomed out at $18.83. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Myriad Genetics, Inc.'s stock market.

Liquidity Ratios

Analyzing MYGN liquidity ratios reveals its financial health of the firm. The current ratio of 126.80% gauges short-term asset coverage for liabilities. The quick ratio (96.27%) assesses immediate liquidity, while the cash ratio (36.31%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio126.80%
Quick Ratio96.27%
Cash Ratio36.31%

Profitability Ratios

MYGN profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -38.40% underscores its earnings before tax deductions. The effective tax rate stands at 3.37%, revealing its tax efficiency. The net income per EBT, 97.30%, and the EBT per EBIT, 103.68%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -37.04%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-38.40%
Effective Tax Rate3.37%
Net Income per EBT97.30%
EBT per EBIT103.68%
EBIT per Revenue-37.04%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.27, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding96
Days of Inventory Outstanding40
Operating Cycle97.35
Days of Payables Outstanding54
Cash Conversion Cycle43
Receivables Turnover6.38
Payables Turnover6.74
Inventory Turnover9.10
Fixed Asset Turnover3.27
Asset Turnover0.64

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.78, and free cash flow per share, -1.69, depict cash generation on a per-share basis. The cash per share value, 1.06, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.09, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.78
Free Cash Flow per Share-1.69
Cash per Share1.06
Operating Cash Flow Sales Ratio-0.09
Free Cash Flow to Operating Cash Flow Ratio2.16
Cash Flow Coverage Ratio-0.32
Short Term Coverage Ratio-3.59
Capital Expenditure Coverage Ratio-0.86
Dividend Paid and Capex Coverage Ratio-0.86

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 17.53%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.29, we discern the balance between debt and equity financing. The long-term debt to capitalization, 21.18%, and total debt to capitalization, 22.76%, ratios shed light on its capital structure. An interest coverage of -93.79 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio17.53%
Debt Equity Ratio0.29
Long Term Debt to Capitalization21.18%
Total Debt to Capitalization22.76%
Interest Coverage-93.79
Cash Flow to Debt Ratio-0.32
Company Equity Multiplier1.68

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 8.42, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.39, reflects the portion of profit attributed to each share. The book value per share, 10.99, represents the net asset value distributed per share, while the tangible book value per share, 2.72, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share8.42
Net Income Per Share-1.39
Book Value Per Share10.99
Tangible Book Value Per Share2.72
Shareholders Equity Per Share10.99
Interest Debt Per Share1.84
Capex Per Share-0.56

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -1.77%, indicates top-line expansion, while the gross profit growth, -3.37%, reveals profitability trends. EBIT growth, -154.00%, and operating income growth, -154.00%, offer insights into operational profitability progression. The net income growth, -311.76%, showcases bottom-line expansion, and the EPS growth, -297.14%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-1.77%
Gross Profit Growth-3.37%
EBIT Growth-154.00%
Operating Income Growth-154.00%
Net Income Growth-311.76%
EPS Growth-297.14%
EPS Diluted Growth-297.14%
Weighted Average Shares Growth3.68%
Weighted Average Shares Diluted Growth3.33%
Operating Cash Flow Growth-684.07%
Free Cash Flow Growth-75900.00%
10-Year Revenue Growth per Share11.15%
5-Year Revenue Growth per Share-24.37%
3-Year Revenue Growth per Share-27.29%
10-Year Operating CF Growth per Share-161.42%
5-Year Operating CF Growth per Share-179.00%
3-Year Operating CF Growth per Share-215.85%
10-Year Net Income Growth per Share-176.47%
5-Year Net Income Growth per Share-173.64%
3-Year Net Income Growth per Share-2320.98%
10-Year Shareholders Equity Growth per Share22.14%
5-Year Shareholders Equity Growth per Share-20.93%
3-Year Shareholders Equity Growth per Share-25.80%
3-Year Dividend per Share Growth per Share-100.00%
Receivables Growth11.28%
Inventory Growth31.37%
Asset Growth-9.24%
Book Value per Share Growth-11.72%
Debt Growth57.10%
R&D Expense Growth4.27%
SGA Expenses Growth-14.19%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 1,257,251,070.89, captures the company's total value, considering both debt and equity. Income quality, 0.95, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.76, gauges operational efficiency, while the research and development to revenue, 12.59%, highlights investment in innovation. The ratio of intangibles to total assets, 55.60%, indicates the value of non-physical assets, and capex to operating cash flow, 42.62%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value1,257,251,070.89
Income Quality0.95
Sales General and Administrative to Revenue0.76
Research and Development to Revenue12.59%
Intangibles to Total Assets55.60%
Capex to Operating Cash Flow42.62%
Capex to Revenue-6.68%
Capex to Depreciation-85.96%
Stock-Based Compensation to Revenue5.62%
Graham Number18.54
Return on Tangible Assets-21.04%
Graham Net Net-1.39
Working Capital137,400,000
Tangible Asset Value219,300,000
Net Current Asset Value-38,300,000
Average Receivables96,450,000
Average Payables29,200,000
Average Inventory17,700,000
Days Sales Outstanding55
Days Payables Outstanding52
Days of Inventory On Hand36
ROIC-9.56%
ROE-0.13%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.02, and the price to book ratio, 3.02, reflect the market's valuation relative to the company's book value. The price to sales ratio, 3.09, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -16.41, and price to operating cash flows, -32.30, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.02
Price to Book Ratio3.02
Price to Sales Ratio3.09
Price Cash Flow Ratio-32.30
Price Earnings to Growth Ratio-0.40
Enterprise Value Multiple-10.09
Price Fair Value3.02
Price to Operating Cash Flow Ratio-32.30
Price to Free Cash Flows Ratio-16.41
Price to Tangible Book Ratio1.32
Enterprise Value to Sales1.85
Enterprise Value Over EBITDA-18.54
EV to Operating Cash Flow-11.83
Earnings Yield-9.58%
Free Cash Flow Yield-12.97%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Myriad Genetics, Inc. (MYGN) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -7.521 in 2024.

What is the ticker symbol of Myriad Genetics, Inc. stock?

The ticker symbol of Myriad Genetics, Inc. stock is MYGN.

What is company IPO date?

IPO date of Myriad Genetics, Inc. is 1995-10-06.

What is company current share price?

Current share price is 21.600 USD.

What is stock market cap today?

The market cap of stock today is 1941297840.000.

What is PEG ratio in 2024?

The current -0.401 is -0.401 in 2024.

What is the number of employees in 2024?

In 2024 the company has 2700.